Akari Therapeutics Reports Q3 2026 Results; Cash of $5.7 Million

Akari Therapeutics reported a third-quarter 2026 net loss of $4.8 million and ended the period with $5.7 million in cash. Operating expenses were $4.7 million, down from $7.4 million a year earlier, when the quarter included an impairment charge related to its former PHP-303 program. The company al…